Making advances in the fight against urological cancers
Thanks to the support of many generous donors, our team of clinicians and researchers are working on groundbreaking clinical trials for all urological cancers.
The TOUR (Translational Oncology and Urology Research) team aims to turn the latest research into medical practice and to improve patient treatments and outcomes in bladder, prostate, renal and testicular cancers both at Guy’s and throughout the world.
Here is a selection of the many projects the team are working on:
Although bladder cancer is the seventh most common cancer in the UK, proportionally it has much less research funding than breast or prostate cancer. However, in July 2017, the TOUR team was awarded a transformational donation to establish a bladder cancer biobank, with the aim of advancing knowledge and treatment of bladder cancer.
The team is working on several clinical trials – four of these are examining treatments that boost the body’s own immune system in the fight against cancer. These trials are testing if treatments can be more effective than those currently available, and if they can be used, post-surgery, to prevent cancer returning.
Guy’s and St Thomas’ Prostate Cancer Service is amongst the busiest in the world with over 1,000 newly diagnosed cases a year and, due to the diversity of our catchment area, our prostate cancer biobank, established in 2013, has provided an outstanding platform for research.
One of many trials the team is looking at is the STAMPEDE trial. This successful trial showed that chemotherapy dramatically improves survival for men with advanced prostate cancer and this approach is now routinely used.
Each year in the UK, 12,500 people are diagnosed with renal cancer. For those whose cancer has already spread at the point of diagnosis, the average survival is three years.
Since 2005, however, seven new drugs have been shown to increase survival rates. The team has been involved in four of the pivotal trials that introduced these drugs and they have benefited many at Guy’s and thousands of patients around the world.
Testicular cancer is the most common cancer of young men and whilst curable it causes significant side effects including distress and long-term toxicity.
The team are involved in several trials looking to improve treatment of testicular cancer. This includes lowering the amount of curative treatment given to avoid long-term toxicity and looking at the genetics of testicular cancer to see if the risk is passed on between generations.
One of the UK’s leading providers of care and treatment for people with cancer